Introduction
Alcoholic liver disease (ALD) is the second most frequent indication for liver transplantation in the USA and Europe [1] . The vast majority of heavy drinkers develop fatty liver [2] , of whom about one-third will progress to liver cirrhosis if they continue to use alcohol [3] . The reasons why only a small subset of exposed individuals develop liver disease is still not understood, and genetic susceptibility may probably play a role, as suggested by studies with twins [4] .
Angiogenesis activation parallels fibrosis progression and hepatocarcinogenesis. In fact, a major inducer of proangiogenic factors is tissue hypoxia, which leads to the activation of hypoxia-induced factors (HIFs) and transcription factors that regulate expression of several targets, not only proangiogenic, but also profibrogenic and pro-oncogenic proteins [5] . In chronic liver disease, several factors promote tissue hypoxia: compression of portal and central venules by fibrotic scar tissue, intrahepatic shunts, and capillarization of hepatic sinusoids, among others [6] . In ALD, hypoxia seems to be even more important, as alcohol intake increases hepatic oxygen consumption, with a smaller increase in oxygen delivery, resulting in central venous hypoxia [7] . Chronic alcohol intake leads to upregulation of HIF-1a and HIF activation in animal models and humans [8] .
Activated HIF consists of two subunits: a and b. There are three a subunits, 1-3, the first two being implicated in angiogenesis. In normoxia, HIFa hydroxylation, by prolyl hydroxylases, increases the binding affinity of HIF to an E3 ubiquitin ligase complex that contains von Hippel-Lindau protein. This favors polyubiquitination, which targets it for proteasomal degradation. During hypoxia, HIFa escapes hydroxylation, being free to form dimers with HIFb and then translocate to the nucleus, where it binds to the promoter of several target genes [9] , such as vascular endothelial growth factor (VEGF). There are five genes in the VEGF family, VEGFA being a key factor in the induction of angiogenesis and vasculogenesis. They act through three receptors, vascular endothelial growth factor receptors (VEGFRs) 1-3, the first two being recognized as having an important role in this process [6] .
Several lines of evidence suggest what the role of these proangiogenic factors in chronic liver disease might be. HIF-1a deficiency protects from fibrosis with less production of profibrogenic mediators in vitro and in the bile duct ligation mouse model [10, 11] . HIF and VEGF levels are increased early on in chronic liver disease [11, 12] . VEGF can directly stimulate proliferation and activation of hepatic stellate cells promoting a1-procollagen expression [13] . Also, in the tetrachloride carbon-induced fibrosis mouse model, administration of monoclonal antibodies against VEGFR1 or 2 decreased fibrosis progression, more efficiently with the latter. The simultaneous administration of both anti-VEGFR antibodies almost completely attenuated fibrosis development [13] . Finally, administration of sorafenib, a multiple receptor tyrosine kinase inhibitor, acting, among others, on VEGFRs, improved portal hypertension and decreased fibrogenesis in animal models of liver cirrhosis [14, 15] . In hepatocellular carcinoma (HCC), VEGF and HIF levels correlate with stage, prognosis, and recurrence [16] [17] [18] [19] [20] .
We aimed to evaluate a possible association between functional polymorphisms in HIF-1a, VEGF, and KDR (encoding VEGFR2) and the risk of developing liver cirrhosis and HCC in heavy drinkers.
Materials and methods

Patients
We performed a case-control study with prospective and consecutive enrollment of patients. Patients were recruited from the Hepatology Unit and the Alcoholism Unit of the Santa Maria University Hospital, Lisbon, Portugal, and from an Alcoholic Rehabilitation Center from the same city, during 2002. All patients had their alcohol intake assessed using a semistructured questionnaire.
Inclusion criteria were as follows: alcohol consumption of at least 80 g/day for at least 5 years, age greater than 18 years, and agreement to participate in the study. Current abstinence was accepted. Exclusion criteria were as follows: positivity to hepatitis B virus surface antigen or antihepatitis C virus antibody; other type of liver disease, namely primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, or a1-antitrypsin deficiency; treatment with potentially hepatotoxic drugs within 6 months of enrollment; and mild abnormalities of liver blood tests, that is aminotransferases lower than twice the upper normal limit, with no clinical signs of liver disease, as it would thus be impossible to exclude liver disease without liver biopsy, which was deemed unethical.
In all, 313 patients were selected, of whom 213 were enrolled and 100 were excluded. Causes of exclusion were chronic infection with hepatotropic viruses in 13 patients, metabolic disease in one patient, and impossibility of excluding liver disease in 86 patients.
Patients were classified into two groups: 125 with ALD and 88 without liver disease (NLD). ALD was defined by the presence of a medical history of hepatic decompensation, that is ascites, hepatic encephalopathy, and/or variceal bleeding, or, in 18 patients, the histological confirmation of liver cirrhosis. NLD was considered in the absence of a medical history of hepatic decompensation, physical stigmata of chronic liver disease, namely cutaneous signs, hepatosplenomegaly, gynecomastia, and testicular atrophy, and at least two normal determinations of blood liver tests, with an exception of an isolated increase in g-glutamyltranspeptidase. NLD heavy drinkers were recalled after 9 years, and only those who did not have clinical evidence of hepatic decompensation and who maintained normal liver tests were included in the present study.
Patients with ALD were followed for up to 9 years, and 26 patients developed HCC. HCC was diagnosed according to histological assessment or at least two imaging studies with intravenous contrast showing a liver nodule with hypervascularization in the arterial phase and washout in the portal phase, according to current guidelines.
All participants gave written informed consent, and the study was approved by the ethics committees of the institutions that were involved.
Laboratory tests
A blood sample (20 ml) was collected for liver tests (aminotransferases, bilirubin, alkaline phosphatase, g-glutamyltranspeptidase, protein electrophoresis, and prothrombin time) and to discard other causes of chronic liver disease (iron, ferritin, total iron-binding capacity, ceruloplasmin, a1-antitrypsin, antinuclear antibodies, smooth muscle antibodies, antimitochondrial antibodies, and serological markers of hepatitis B virus and hepatitis C virus infection). All were analyzed in the central pathology department using routine methods.
Genetic polymorphisms
The following criteria were used to select genes for the study: the gene should be part of a pathway for which there is a credible scientific basis to support its involvement in angiogenesis; the gene has an established, well-documented genetic polymorphism; the frequency of the polymorphism is high enough so that its impact on chronic liver disease risk at a population level will be meaningful; and/or the polymorphism has some degree of likelihood to alter the function of the gene in a biologically relevant manner. Three polymorphisms were selected: 1744C/T in gene HIF-1a on chromosome 14, which results in the substitution of proline to serine in residue 582, with a minor allele frequency (MAF) of 0.073 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs = rs11549465); 2578C/A in gene VEGFA, chromosome 6, with a MAF of 0.342 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs = rs699947); and 1416A/T in gene KDR, which encodes for VEGFR2 and results in the substitution of a glutamine for histidine in residue 472, with an MAF of 0.235 (http://www.ncbi.nlm. nih.gov/SNP/snp_ref.cgi?rs = rs1870377). MAFs are according to 1000 genome description.
Genomic DNA was extracted from 0.2 ml of blood using the QIAamp DNA Mini Kit (Qiagen, Crawley, UK) according to the supplier's instructions. PCR was performed as a 25-ml reaction using 1.0 U Biotaq DNA polymerase (Bioline, London, UK) and 1 ml extracted genomic DNA as the template (50-500 ng). The DNA was amplified by denaturing at 951C for 5 min, followed by 35 cycles of 951C for 30 s, X1C for 30 s and 721C for 45 s, where X is 641C for HIF-1a and KDR and 611C for VEGFA. The primers used for HIF-1a amplification were as follows: forward: 5 0 -AGGACACAGATTTAGAC TTGG-3 0 and reverse: 5 0 -GTGGCATTAGCAGTAGGT TC-3 0 . VEGFA promoter was amplified using the forward primer 5 0 -GAAATTGCTGCATTCCCATTC-3 0 and the reverse primer 5 0 -CATCCCATTCTTGCATATAGG-3 0 ; however, VEGFR2 was amplified using forward primer 5 0 -gctgcgttggaagttatttc-3 0 and reverse primer 5 0 -TGC CTCACATATTATTGTACC-3 0 . PCR products were sequenced on an automated sequencer ABI PRISMR 3100-Avant using a BigDye v3.1 sequence kit (Applied Biosystems, Foster City, California, USA). Results were analyzed with the in-silico program Sequencher (Gene Codes Corporation, Ann Arbor, Michigan, USA).
Statistical analysis
The primary endpoint was the evaluation of the risk of developing ALD in a population of heavy drinkers, taking into account the allelic frequency of three genetic polymorphisms, either isolated or in conjunction. The secondary endpoint was the risk of developing HCC in patients with ALD, in relation to the allelic frequency of the same polymorphisms.
The sample size was calculated for the polymorphism with the lowest MAF, HIF-1a, 7.3%, assuming a disease prevalence, in the population of heavy drinkers, of 30% [3] , an expected increased risk of having ALD with an odds ratio (OR) of 2.5, a type I error probability for the two-sided test, a value of 0.0167 after Bonferroni correction for multiple testing, and a probability of correctly rejecting the null hypothesis with a power of 0.8, and a ratio of case : controls 1 : 1. Using the Genetic Power Calculation program (http://pngu.mgh.harvard.edu/purcell/gpc/cc2.html), the calculated number of cases required was 113.
After sequencing and genotyping, we determined the Hardy-Weinberg equilibrium using w 2 -tests. We used 
Results
Clinical characteristics
ALD patients were older than NLD individuals (56±11 vs. 50±13 years, P < 0.001), although the sex distribution was not significantly different. NLD patients had a higher alcohol consumption than ALD patients (331±293 vs. 215±164 g/day). As expected, NLD individuals presented normal hepatic blood tests, whereas ALD patients had abnormal results. Characteristics are summarized in Tables 1 and 2 .
Genetic polymorphisms and risk of alcoholic liver disease
We found no significant differences in genotypes or allele frequencies in the polymorphisms HIF-1a 1744C/T, KDR 1416A/T, or VEGFA 2578C/A, individually or in association, in heavy drinkers with or without liver disease (Table 3) .
Genetic polymorphisms and risk of hepatocellular carcinoma
In ALD patients, the T allele of the polymorphism 1416A/T in gene KDR, which encodes VEGFR2, was more frequent in patients who developed HCC (36 vs No differences were found in allelic frequencies or genotypes in HIF-1a 1744C/T or VEGFA 2578C/A, in ALD patients who developed HCC (Table 3) . However, when considering the simultaneous presence of KDR 1416T and VEGFA 2578A in a dominant pattern, they were associated with an increased risk of developing HCC (OR 3.088; 95% CI 1.20-7.96).
Discussion
In the present study, we asked two questions. The first was regarding the possible association between functional genetic polymorphisms in angiogenic factors HIF-1a 1744C/T, VEGFA 2578C/A, and KDR 1416A/T and the risk of having chronic liver disease in heavy drinkers, and the second evaluated the possibility that the abovementioned polymorphisms could associate with an increased risk of HCC among ALD patients. Regarding the first question, no association was found. This is a definitive study, as the study was powered for it and the selection of cases and controls was highly rigorous. In fact, all patients had either liver biopsy or unequivocal clinical evidence of liver cirrhosis. In all individuals, other causes of liver disease were extensively excluded. In contrast, the selection of controls was a target of high scrutiny, leading to exclusion of one-third of candidates. Performing a liver biopsy would be the unequivocal confirmation of a healthy liver; however, it would obviously be unethical to perform a potentially hazardous procedure in a healthy individual. Furthermore, even liver biopsy would have the problem of a sampling error. Our NLD cohort had no clinical evidence of liver disease and presented two separated liver tests, apart by more than 6 months, with no abnormalities. If a second liver test was not available, the patient would not be included. Those individuals were recalled 9 years later, and were included only if they maintained normal liver tests and did not present clinical decompensation of liver disease.
Regarding the second question, we in fact found an association of the 1416T allele in the gene of VEGFR2 with a more than 2.5-fold increased risk of HCC in the ALD patients. Also, our data suggest a dominant pattern Table 3 Polymorphisms HIF-1a 1744C/T, VEGFR2 1416A/T, and VEGFA 2578C/A in heavy drinkers and the risk of developing ALD ALD patients (n = 125) NLD patients (n = 88) P value HIF-1a 1744C/T Genotype (%) CC 77%, CT 21%, TT 2% CC 78%, CT 22%, TT 0% 0.531 T allele frequency (%) 13 ALD, alcoholic liver disease; HIF-1a, hypoxia-induced factor-1a; NLD, nonliver disease; VEGFA, vascular endothelial growth factor A; VEGFR2, vascular endothelial growth factor receptor 2. Bold highlights the significant differences. ALD, alcoholic liver disease; HCC, hepatocellular carcinoma; HIF-1a, hypoxia-induced factor-1a; VEGFA, vascular endothelial growth factor A; VEGFR2, vascular endothelial growth factor receptor 2.
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of risk transmission for that polymorphism. It should be stated, however, that this association lost significance when adjusted for age. This could be due to the fact that the study was powered for the risk of developing ALD and not HCC, and so these results should be further confirmed. We also found that the simultaneous presence of polymorphisms in VEGFA and KDR genes was associated with a threefold risk of developing HCC. Again, although this is a subgroup analysis with a small number of patients with HCC, the fact that we did find differences may reflect the cautious follow-up of these patients. This is not merely a transversal study, and although we do not have information of the duration of the diagnosis of liver cirrhosis, the patients were followed in a tertiary center for up to 9 years (less if they died in between) and subjected to HCC screening. We acknowledge though that it merits further study in a larger population.
Several mechanisms could explain this association. In fact, HIF-1a binds to the E3 ubiquitin ligase complex with von Hippel-Lindau protein through the minimal N-terminal transactivation domain within the oxygen-dependent degradation domain. The binding affinity depends on an oxygen-sensitive hydroxylation of a critical proline residue in the N-terminal transactivation domain, in position 582. The polymorphism 1744C/T, which leads to the substitution of proline to serine in position 582, decreases that affinity, increasing the activation of HIF and its transcriptional activity [21] . VEGFA 2578C/A is a polymorphism in the promoter of VEGFA that is known to be associated with increased levels of VEGF [22] . KDR 1416A/T is a polymorphism in the gene of VEGFR2 that leads to the substitution of glutamine to histidine in position 472. This residue localizes in the fifth immunoglobulin-like (Ig-like) domain that contains structural features that inhibit VEGFR2 signaling in the absence of VEGF [23] . The p.Q472H polymorphism has been shown to lead to a 46% increase in receptor phosphorylation after binding to VEGF [24] and to cause a mild increase in the binding efficiency. Presumably, it should also increase autophosphorylation [25] .
HCC is a highly vascularized tumor dependent on neovascularization. In fact, an animal model of HCC has shown that VEGF, the main angiogenic factor, augments HCC development and metastasis potential [26] . There is a progressive increase in liver expression of VEGF from low-grade dysplasia, high-grade dysplasia, and early HCC [27] . Also, VEGF and VEGFR2 hepatic expression, and VEGF plasma levels, correlate with a high HCC tumor grade, size, vascular invasion, and metastasis potential [28] [29] [30] [31] . Similarly, HIF-1a hepatic expression is associated with the development and prognosis of HCC and its plasma levels may help in the diagnosis and in treatment monitoring in HCC [32] .
Several studies have already evaluated genetic polymorphisms in VEGFA and HIF-1a in HCC, with discrepant results. The polymorphism in the VEGF promoter 2578C/A did not show an association with HCC, when 93 patients were compared with 99 healthy controls [33] . However, the -2578AA genotype was associated with a larger tumor size, a higher tumor number, nodal invasion, an advanced Barcelona Clinic Liver Cancer (BCLC) stage, and decreased survival in a sample of 416 patients with HCC [34] . Another VEGFA polymorphism (-936C/T) presented a higher frequency of C allele in association with the risk of HCC in patients when compared with patients with liver cirrhosis [35] , but not when compared with healthy controls [33] . Also, a polymorphism in an intronic region, rs3025035, showed an association with recurrence and overall survival in patients with HCC subjected to liver transplant [33] . Lastly, a recent large study on chronic hepatitis C found two other functional polymorphisms in VEGFA promoters, rs833061 and rs1570360, that associated with an increased risk of HCC [36] . Regarding genetic polymorphisms on HIF-1a, Hsiao et al. [37] studied 102 HCC patients and 347 healthy controls, and found that the substitution of alanine by threonine in position 588 (p.A588T) was associated with HCC, showing a synergic effect with alcohol consumption. However, they failed to demonstrate an association with the substitution of proline to serine in position 582 (p.P582S), the same polymorphism we analyzed. To our knowledge, polymorphisms in KDR have not yet been studied, either in ALD or in HCC.
For future studies, it would be interesting to evaluate a possible interaction between the polymorphisms in these proangiogenic hypoxia-inducible factors and polymorphisms and hepatic levels of cytochrome P450 2E1 (CYP2E1) in hepatocarcinogenesis associated with ALD. In fact, not only does alcohol induce CYP2E1 [38] , but the latter has recently been shown to promote liver hypoxia and HIF-1a activation [39] . Also, increased expression of CYP2E1 was demonstrated in premalignant cells in an animal model of ethanol-induced HCC [40] .
Of note, among ALD patients, those who developed HCC had lower aminotransferase baseline level. Although the aminotransferase level has not been shown to be associated with a risk of HCC development in ALD [41] , it may reflect a more effective mechanism of clearance of premalignant cells, due to increased apoptosis. Indeed, a frequent phenomenon in HCC is the failure of premalignant transformed cells undergoing apoptosis [42] .
Conclusion
Functional genetic polymorphisms in proangiogenic factors, HIF-1a 1744C/T, VEGFA 2578C/A, and KDR 1416A/T, are not associated with the risk of developing chronic liver disease in heavy drinkers. However, 1416A/T seems to more than double the risk of HCC development in patients with ALD. The simultaneous presence of the latter and VEGFA 2578C/A seems to further increase that risk.
